Oramed Pharmaceuticals INC 8-K filings

Oramed Pharmaceuticals Inc. announced amendments to its bylaws regarding stockholder action by written consent and an extension for Scilex Holding Company's payment obligations on outstanding promissory notes.

Oramed Pharmaceuticals Inc. announced the completion of its sale of Oratech Pharma to Lifeward Ltd. and a concurrent $9 million investment in Lifeward.

Oramed Pharmaceuticals Inc. has announced a strategic transaction to transfer its oral drug delivery technology to Lifeward Ltd., becoming a significant shareholder and investor in the medical robotics company.

Oramed Pharmaceuticals announced an $18 million payment from Scilex Holdings, bringing total returns to $118 million, and approved a $0.25 per share cash dividend.

Leonard Sanks has resigned from the Board of Directors of Oramed Pharmaceuticals Inc., effective January 1, 2026, after 18 years of service.

Oramed Pharmaceuticals Inc. announced the completion of the repurchase of all remaining Scilex warrants, totaling $28.5 million in aggregate payments.

Oramed Pharmaceuticals announced strong unaudited financial results for the nine months ended September 30, 2025, driven by strategic investments and a 42% increase in total assets.

Oramed Pharmaceuticals Inc. has implemented a shareholder rights plan, commonly known as a 'poison pill,' to protect against hostile takeovers and ensure fair treatment for all stockholders.

Oramed Pharmaceuticals repurchased shares, terminated a joint venture, and announced progress in its oral insulin program and diversified investment portfolio.

Oramed Pharmaceuticals Inc. announced Scilex Holding Company repurchased the first tranche of warrants for $13 million, part of a larger $27 million agreement.

Oramed Pharmaceuticals Inc. stockholders approved an increase of 2,000,000 shares for the 2019 Stock Incentive Plan and re-elected all directors at their 2025 Annual Meeting.

Oramed Pharmaceuticals Inc. has entered into an agreement granting Scilex Holding Company an option to repurchase 6.5 million warrants for $27 million, which, if exercised, will extend the maturity of a $101.875 million promissory note.

Oramed Pharmaceuticals' Board of Directors has authorized a one-year extension to its existing stock buyback program, allowing the company to repurchase up to $20 million of its common stock.

Oramed Pharmaceuticals announces a $36.9 million investment in Alpha Tau Medical, alongside a strategic collaboration to support Alpha Tau's cancer therapy technology.

Oramed Pharmaceuticals amends agreements with Scilex, acquiring royalty rights on Gloperba and Elyxyb and securing a worldwide license for Gloperba outside the U.S.

Oramed Pharmaceuticals' RoyaltyVest Ltd. has entered into a license agreement with Scilex Pharmaceuticals for the worldwide rights to ZTlido and other lidocaine products outside of the United States.

Oramed Pharmaceuticals is spinning off its oral drug delivery technology into a new joint venture, OraTech Pharmaceuticals, with Hefei Tianhui Biotech Co., Ltd. (HTIT), to accelerate the development and commercialization of oral insulin.

Oramed Pharmaceuticals has amended its senior secured promissory note with Scilex Holding Company, extending the maturity date and receiving shares of Scilex common stock in return.

Oramed Pharmaceuticals has agreed to defer a debt payment from Scilex Holding Company in exchange for shares, royalty rights, and potential future funding opportunities.

Oramed Pharmaceuticals Inc. received a $13.2 million payment from Scilex Holding Company, significantly reducing the outstanding principal balance on a series of promissory notes.

Oramed Pharmaceuticals has reduced its outstanding debt by $25 million through a refinancing agreement with Scilex and an additional $1 million payment.

Scilex Holding Company has finalized a $50 million financing round, while Oramed Pharmaceuticals restructures its existing debt with Scilex, gaining new convertible notes and warrants.

Oramed Pharmaceuticals has engaged InClin, Inc. as a clinical research organization to support its upcoming Phase 3 trial for ORMD-0801, a treatment for type 2 diabetes.

Oramed Pharmaceuticals and Scilex Holding Company have agreed to amend their existing loan agreement, including a $2 million payment from Scilex to Oramed, a warrant purchase, and an extension of a $20 million amortization payment.

Oramed Pharmaceuticals Inc. successfully held its 2024 Annual Meeting of Stockholders, re-electing all nominated directors and ratifying its independent auditor.

Oramed Pharmaceuticals has authorized a stock buyback program allowing the company to repurchase up to $20 million of its common stock over the next 12 months.

Oramed Pharmaceuticals received a $10.4 million payment from Scilex, completing a $20 million principal payment obligation under a previously established agreement.

Oramed Pharmaceuticals has appointed Avraham Gabay as its new Chief Financial Officer, Treasurer, and Secretary, effective June 18, 2024.

Oramed Pharmaceuticals' Chief Financial Officer, David Silberman, has resigned for personal reasons, effective July 12, 2024, and the company has begun the search for a replacement.

Oramed Pharmaceuticals received a $9.6 million prepayment from Scilex, reducing the upcoming June principal payment on a secured promissory note.